SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to a reported surge in revenue and a small float, sparking excitement about a potential massive run. The community is focused on the stock's low float and are watching for news catalysts, drawing comparisons to other stocks with similar setups. Some traders are also pointing to the stock's chart patterns as a reason for optimism.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending due to discussions surrounding Amazon's competitive moves in the DSP space, sparking debates about market share and potential impacts. The community is analyzing Amazon's recent offer of head-to-head testing and ADWEEK's reporting of it. Investors are closely watching Trade Desk's response and its long-term strategies in a competitive landscape.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending as traders discuss a potential short squeeze, noting high borrowing costs and a seemingly limited float. Community members are debating the impact of insider activity and monitoring short interest data. Some investors suggest a buy-and-hold strategy, while others point to technical indicators.

Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. It develops the first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world. The company is headquartered in Tucson, AZ.

Picard Medical Inc.

Picard Medical (PMI) is trending amid significant stock volatility, prompting the company to release a statement clarifying they are unaware of any undisclosed material changes. The community is actively discussing potential dilution, short covering, and speculating about a possible pump and dump, while some remain bullish, citing the company's unique position in the artificial heart market.

ETHZilla Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palm Beach, FL.

ETHZilla Corp

ETHZilla Corporation

ETHZ is trending as investors discuss its potential undervaluation relative to its Ethereum holdings, amplified by interest from meme stock communities and the disclosed stake of an activist investor. Community talking points revolve around its asset value, potential for a short squeeze given the low float, and comparison to other Ethereum treasury plays. However, concerns persist regarding potential dilution from convertible notes and the company's cash burn.

Meet DragonWifBeard: The world's first AI-powered pet dragon!  More Than Just Scales: DragonWifBeard is a real-life bearded dragon revolutionizing the pet experience. He's not just any reptile – he's equipped with cutting-edge Eliza AI agent, giving him a unique personality and the ability to interact with his environment in unprecedented ways. The Future of Companionship: This groundbreaking project merges the love for pets with the limitless possibilities of AI. Witness the dawn of a new era in companionship with DragonWithBeard.

DragonWifBeard

DragonWifBeard ($DWB) is trending as the community emphasizes its potential for profit, particularly its availability on Phantom Wallet. The conversation highlights a blend of 'ancient' and 'modern' gains, with users frequently mentioning fire and wisdom as key themes. The coin's association with other Solana tokens is also part of the discussion.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

NEUP is trending due to a significant surge, potentially driven by insider buying and a milestone payment from Merck related to their Alzheimer's program. The community is focused on the stock's low float and the potential for a short squeeze, with some expecting a continued upward trend. However, some traders are also discussing the possibility of dilution impacting future price action.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community anticipates its upcoming listing on Kraken, which many believe will increase accessibility and drive the price up.  Discussions revolve around potential institutional investment and the impact of the listing amidst existing partnerships and a new website launch.  However, some traders express concern about potential shorting and the token's ability to hold gains, with a few skeptical voices calling it a scam.

Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.

Genenta Science SpA - ADR

GNTA is trending due to high volatility and a massive intraday price swing, with community members debating whether the move is a pump and dump or a genuine short squeeze opportunity. A partnership announcement with Anemocyte is cited as a potential catalyst, though some traders question the magnitude of the price action relative to the news. Discussions also include speculation about potential short covering and the possibility of further upward movement.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd. - ADR

Teva is trending as community members discuss its potential and setbacks, with some pointing to a recent FDA approval for Uzedy as a positive catalyst. Despite some positive news, negative sentiment persists regarding the stock's performance and leadership. Analysts are weighing in, with price target adjustments and discussions around the company's "Pivot to Growth" strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics Inc. (13% jump in followers)Candel Therapeutics Inc. shares gained momentum as Wall Street analysts&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">highlighted</a> the potential of its lead cancer drug candidate, CAN-2409. Canaccord expects continued clinical success in prostate, pancreatic, and non-small cell lung cancer, noting a significant increase in median overall survival in testing so far. Citi’s modeling suggests CAN-2409 could extend survival in localized prostate cancer by as much as eight to nine years over radiotherapy alone.&nbsp;The stock is up over 35% year-to-date.Acelyrin Inc. (12% jump in followers)Acelyrin confirmed that Concentra Biosciences, controlled by Tang Capital Partners, submitted an unsolicited offer to acquire all outstanding shares of Acelyrin for $3.00 per share in cash, plus a contingent value right tied to future licensing or asset sales.Earlier in the month, Acelyrin announced a merger agreement with Alumis in an all-stock transaction expected to close in the second quarter of 2025, pending shareholder approval.&nbsp;Acelyrin stock is down over 18% year-to-date.Solid Biosciences Inc. (11% jump in followers)Solid Biosciences shares surged after early-stage data from its gene therapy candidate SGT-003 for Duchenne muscular dystrophy&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sldb-stock-soars-on-dmd-trial-data/ch5rNeJRvt">showed</a> promising results.&nbsp;Following the data release, Chardan raised its price target on the stock and increased the therapy’s probability of success to 48%, citing strong early efficacy signals and manageable safety risks.Solid Biosciences stock is up 43% year-to-date.Estrella Immunopharma Inc. (11% jump in followers)Estrella Immunopharma received a bullish initiation from D. Boral Capital, which started coverage with a ‘Buy’ rating and a $16 price target. The firm sees Estrella as a potential major player in immuno-oncology, with its EB103 therapy using ARTEMIS T-cell engineering technology to target solid tumors.&nbsp;The company also completed the first dose cohort in its Phase I/II trial, receiving approval from the Data and Safety Monitoring Board to proceed to the second dose level.&nbsp;Estrella stock is up over 22% year-to-date.Aditxt Inc. (10% jump in followers)Aditxt announced that its subsidiary, Pearsanta, has engaged Dominari Securities as the lead underwriter for its planned initial public offering. The IPO aims to support Pearsanta’s U.S. and international commercial launch of its Mitomic Technology platform for early cancer detection.&nbsp;Pearsanta is developing a non-invasive blood test to detect cancer at earlier stages by leveraging mitochondrial DNA deletions as biomarkers. IPO proceeds will fund the U.S. launch of its Laboratory Developed Tests (LDTs) and drive global commercialization through distribution partnerships and regulatory approvals.&nbsp;Aditxt stock is down over 53% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

Equity

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.


Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc...

Shares of Aditxt Inc. (ADTX) slipped in Thursday’s after-hours session after a more than 7% drop during regular trading.&nbsp;Despite the pullback, the penny stock remains up over 45% in the past week as retail interest builds ahead of a key company update.CEO Amro Albanna is set to host a virtual fireside chat on Friday, Feb. 21, at 11:30 AM ET, where he will discuss corporate developments, subsidiary updates, potential transactions, and pipeline advancements.&nbsp;The event will cover&nbsp;subsidiary Adimune, Inc. and its focus on autoimmunity treatments, including Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome.Albanna will also touch upon another subsidiary, Pearsanta Inc., discussing its progress in early cancer detection and its planned IPO in 2025.<stembedurl>https://stocktwits.com/Ztraderguy/message/604934960</stembedurl><stembedurl>https://stocktwits.com/Ronin2024/message/605087805</stembedurl>Aditxt, which has lost over 99% of its value in the past year, has been on an acquisition spree to strengthen its portfolio.&nbsp;In October, the company outlined its year-end plans, including acquisitions of Evofem Biosciences (EVFM) and Appili Therapeutics (APLIF), which generated $7.8 million in revenue for the six months ended June 30, 2024.With a market cap under $10 million, Aditxt said in October that it is working to clean up its balance sheet, reduce its $19 million in accounts payable, and secure funding to complete its planned acquisitions.&nbsp;Albanna previously highlighted the company’s Nasdaq listing, debt reduction, and strategic capital access as critical to its future.Shares of Aditxt are down over 39% year-to-date. Short interest soared from 0.7% at the beginning of 2025 to 9.3% by the end of last week, according to Koyfin data.Retail traders will be closely watching Friday’s event for potential catalysts that could drive further price action.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Microcap Biotech Aditxt Rallies Retail Interest Ahead Of CEO’s Fireside Chat: What’s On Investors’ Radar?

The event will cover Adimune, Inc., which focuses on autoimmunity treatments, and subsidiary Pearsanta's planned IPO in 2025.

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Aditxt, Inc. (Aditxt or the Company) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced that it will host a virtual Fireside Chat on...

Aditxts Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform dedicated to accelerating promising health innovations, is pleased to announce that its Board of Directors has...

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Adimune, Inc. (Adimune...

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 PR Newswire SAN DIEGO, Nov. 14, 2024 Improved...

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform dedicated to accelerating promising health innovations, today provided an update to its shareholders on the...

Aditxts Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target...

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform dedicated to accelerating promising health innovations, announced today that its acquisition target, Evofem...

Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Mountain View, CA.

Aditxt Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

ADTX
Aditxt Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ADTX News

ADTXAditxt Inc